Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL6423269 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL15159339 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL319903 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423273 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12864552 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL18926545 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL13840952 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL10061862 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109293613-B | Epidaunorubicin intermediate compound | 鲁南制药集团股份有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-109942647-B | Method for synthesizing epirubicin intermediate body surface daunorubicin | 鲁南制药集团股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-11371026-B2 | DoxA protein mutant, and coding gene and applications thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-06-28 | — | — | US | claimed |
| CN-110283170-B | Preparation of compound and application of compound in inhibiting growth of various tumor cells | 清华大学 | 2020-11-06 | — | — | CN | claimed |
| CN-107693487-B | Anthracycline antitumor antibiotic compound micelle and preparation method and application thereof | 烟台大学 | 2020-03-24 | — | — | CN | claimed |
| CN-106282042-B | Streptomyces boscalis and method for producing epidaunorubicin by using same | 浙江海正药业股份有限公司 | 2019-12-10 | — | — | CN | claimed |
| US-10081652-B2 | Purification of epidaunorubicin | Medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2018-09-25 | — | — | US | claimed |
| EP-3137475-B1 | PURIFICATION OF EPIDAUNORUBICIN | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2018-06-27 | — | — | EP | claimed |
| EP-1990405-B1 | Genetically modified strains producing anthracycline metabolites useful as cancer drugs | PROVIVO OY (FI) | 2017-07-26 | — | — | EP | claimed |
| EP-3137475-A1 | PURIFICATION OF EPIDAUNORUBICIN | medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2017-03-08 | — | — | EP | claimed |
| EP-1990405-A1 | Genetically modified strains producing anthracycline metabolites useful as cancer drugs | W. C. Heraeus GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| EP-1814525-A2 | STABLE LYOPHILIZED ANTHRACYCLINE GLYCOSIDES | Sicor Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2007067779-A2 | METHODS AND COMPOSITIONS FOR DRUG DELIVERY ENHANCEMENT | TSRL, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-20070004653-A1 | Stable lyophilized anthracycline glycosides | SICOR, INC. | 2007-01-04 | — | — | US | claimed |
| WO-2006122309-A2 | STABLE LYOPHILIZED ANTHRACYCLINE GLYCOSIDES | SICOR, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| WO-2006111561-A1 | IMPROVED MICROBIAL PRODUCTION OF ANTHRACYCLINS | DSM IP ASSETS B.V. (NL) | 2006-10-26 | — | — | WO | claimed |
| US-5945518-A | Process for the preparation of anthracycline antibiotics | Sicor Societa' Italiana Corticosteroida S.p.A. (IT) | 1999-08-31 | — | — | US | claimed |
| EP-0819132-B1 | A PROCESS FOR THE PREPARATION OF ANTHRACYCLINE ANTIBIOTICS | SICOR SPA (IT) | 1999-06-09 | — | — | EP | claimed |
| EP-0819132-A1 | A PROCESS FOR THE PREPARATION OF ANTHRACYCLINE ANTIBIOTICS | SICOR Società Italiana Corticosteroidi S.p.A. (IT) | 1998-01-21 | — | — | EP | claimed |
| WO-1996029335-A1 | A PROCESS FOR THE PREPARATION OF ANTHRACYCLINE ANTIBIOTICS | SICOR SOCIETA' ITALIANA CORTICOSTEROIDI S.P.A. (IT) | 1996-09-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081652-B2 | Purification of epidaunorubicin | FAU, EFTUD2, DUT | TOP2A 80/4885MEN1 4083/4885THRB 3992/4885 |
| US-20070004653-A1 | Stable lyophilized anthracycline glycosides | TREH, CD38, GANAB | TOP2A 7/4885MEN1 1864/4885THRB 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.